Migraine and the New Anti-CGRP Treatments: Facebook Live with Dr. David Dodick

Описание к видео Migraine and the New Anti-CGRP Treatments: Facebook Live with Dr. David Dodick

In September 2018, fremanezumab (AJOVY™), was approved by the FDA for the treatment and prevention of migraine. The news came four months after the FDA approved the first monoclonal antibody, erenumab (Aimovig™), the first treatment specifically designed to prevent migraine. Clinical trials found both treatments to be effective at reducing headache frequency and also found them to be well tolerated.

During a recent Facebook Live, Dr. David Dodick, Chair of the American Migraine Foundation and Professor of Neurology at the Mayo Clinic Arizona, discussed the latest CGRP advancements with the migraine community.

Комментарии

Информация по комментариям в разработке